ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia cells

International Journal of Oncology

Volumn 41, Issue 2, 2012, Pages 533-540

  Qiu, Lian Nv ^a   Zhou, Yong Lie ^a   Wang, Zhen Ni ^a   Huang, Qiang ^a   Hu, Wei Xiao ^b  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Apoptosis; Chronic B cell lymphocytic leukemia; Mitochondrial membrane potential; Reactive oxidative species; ZGDHu 1

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; N,N' DI(M METHYLPHENYI) 3,6 DIMETHYL 1,4 DIHYDRO 1,2,4,5 TETRAZINE 1,4 DICARBOAMIDE; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; MALE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; MITOCHONDRIAL MEMBRANES; PERMEABILITY; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED;

EID: 84863598556     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1467     Document Type: Article

References (33)

1. Catovsky D, Fooks J and Richards S: Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol 72: 141-149, 1989. (Pubitemid 19151132)
2. Reed JC: Molecular biology of chronic lymphocytic leukemia: implications for therapy. Semin Hematol 35: 3-13, 1998.
3. Jewell AP: Role of apoptosis in the pathogenesis of B-cell chronic lymphocytic leukaemia. Br J Biomed Sci 59: 235-238, 2002.
4. Rassenti LZ, Jain S, Keating MJ, et al: Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112: 1923-1930, 2008.
5. Inoue S, Riley J, Gant TW, Dyer MJ and Cohen GM: Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 21: 1773-1782, 2007. (Pubitemid 47086766)
6. Vogler M, Butterworth M, Majid A, et al: Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113: 4403-4413, 2009.
7. Ly JD, Grubb DR and Lawen A: The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis 8: 115-128, 2003. (Pubitemid 36553052)
8. Kiss T: Apoptosis and its functional significance in molluscs. Apoptosis 15: 313-321, 2010.
9. Simon HU, Haj-Yehia A and Levi-Schaffer F: Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5: 415-418, 2000. (Pubitemid 32162623)
10. Smolewski P, Duechler M, Linke A, et al: Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk Res 30: 1521-1529, 2006. (Pubitemid 44604414)
11. Faderl S, Rai K, Gribben J, et al: Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 107: 916-924, 2006. (Pubitemid 44291139)
12. Liu FT, Agrawal SG, Gribben JG, et al: Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 111: 2797-2805, 2008.
13. Hu WX, Zhou M, Cai ZB and Yang YZ: Synthesis of new type antineoplastic drug 3,6-dimethyl-1,4-dihydro-s-tetrazine-1,4-dicarboamide. Patent, China, 2004.
14. Rao GW and Hu WX: Synthesis, structure analysis, and antitumor activity of 3,6-disubstituted-1,4-dihydro-1,2,4,5-tetrazine derivatives. Bioorg Med Chem Lett 16: 3702-3705, 2006.
15. Zhou Y, Lv Y, Xu W and Hu W: Determination of proteasome activities with fluorogenic kinetic assays and its application in screening proteasome inhibitor. Chi J Clin Phar Therap 10: 1127-1133, 2008.
16. Horie R, Watanabe T, Morishita Y, et al: Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21: 2493-2503, 2002. (Pubitemid 34438102)
17. Martin SJ, Reutelingsperger CP, McGahon AJ, et al: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182: 1545-1556, 1995.
18. Zhu BS, Xing CG, Lin F, Fan XQ, Zhao K and Qin ZH: Blocking NF-kappaB nuclear translocation leads to p53-related autophagy activation and cell apoptosis. World J Gastroenterol 17: 478-487, 2011.
19. Petit PX, Susin SA, Zamzami N, Mignotte B and Kroemer G: Mitochondria and programmed cell death: back to the future. FEBS Lett 396: 7-13, 1996. (Pubitemid 26360271)
20. Shakir FK, Audilet D, Drake AJ III and Shakir KM: A rapid protein determination by modification of the Lowry procedure. Anal Biochem 216: 232-233, 1994. (Pubitemid 24036857)
21. Cory S and Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656, 2002. (Pubitemid 37328916)
22. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
23. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
24. Reed JC: Double identity for proteins of the Bcl-2 family. Nature 387: 773-776, 1997.
25. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998. (Pubitemid 28406819)
26. Chao DT and Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419, 1998. (Pubitemid 28183370)
27. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
28. Nicholson DW, Ali A, Thornberry NA, et al: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43, 1995.
29. Almond JB, Snowden RT, Hunter A, Dinsdale D, Cain K and Cohen GM: Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia 15: 1388-1397, 2001. (Pubitemid 32785308)
30. Duechler M, Linke A, Cebula B, et al: In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol 74: 407-417, 2005. (Pubitemid 40545566)
31. Smolewski P, Duechler M, Linke A, Cebula B, Schwarzmeier JD and Robak T: Cytotoxic effect of proteasome inhibitor bortezomib in combination with ourine nucleoside analogues on chronic lymphocytic leukemia cells in vitro. Blood 104: 288-294, 2004.
32. + regulatory T cells in patients with chronic B cell lymphocytic leukemia in vitro. Chi J Hematol 12: 841-843, 2010.
33. Cuni S, Perez-Aciego P, Perez-Chacon G, et al: A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18: 1391-1400, 2004. (Pubitemid 39136749)